Aurealis Pharma AG
A game changer for chronic wounds, cancer, inflammatory diseases and beyond.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
* | N/A | CHF8.0m | Seed |
| Total Funding | 000k | ||
Aurealis Therapeutics is a pioneering biopharmaceutical company focused on developing advanced therapies for chronic wounds, cancer, and inflammatory diseases. Operating in the healthcare and biotechnology sectors, Aurealis Therapeutics serves patients, healthcare providers, and medical institutions. The company's business model revolves around research and development of novel treatments, leveraging cutting-edge technology to address unmet medical needs. Revenue is generated through partnerships, licensing agreements, and sales of proprietary therapies. Headquartered in Basel, Switzerland, with additional facilities in Kuopio, Finland, Aurealis Therapeutics is strategically positioned to collaborate with global healthcare leaders.
Keywords: biopharmaceutical, chronic wounds, cancer, inflammatory diseases, advanced therapies, healthcare, biotechnology, research, development, proprietary treatments.